Increased sales of its pharmaceutical radioisotopes helped isotope technology firm Eckert & Ziegler to record revenues in the first half of 2019.
For the period (end-June 30), Eckert & Ziegler had revenues of 89 million euros, up 10% from the 81 million euros reported last year. The company highlighted the performance of its radiopharma segment, which increased by 41% to reach 21.7 million euros in revenue thanks to continuing strong pharmaceutical radioisotopes sales results. Revenues from Eckert & Ziegler's isotope products segment grew by 5% to 54.2 million euros. Radiation therapy segment revenues declined, however, by 8% to 13.2 million euros.
The firm had profit of 13.1 million euros, up from 8.5 million euros for the first half of 2018. Looking ahead, Eckert & Ziegler said it expects to report 180 million euros in sales for the 2019 fiscal year, with earnings of around 4.00 euros per share.
